Navigation Links
Roskamp Institute Reports Beneficial Effects of Nutritional Supplementation with Anatabine in an Animal Model of Multiple Sclerosis
Date:5/8/2012

GLEN ALLEN, Va., May 8, 2012 /PRNewswire/ -- Star Scientific, Inc. (NASDAQ: CIGX) through its wholly owned subsidiary, Rock Creek Pharmaceuticals Inc., announces that it has received important new research findings from its research partner, The Roskamp Institute of Sarasota, Florida. The Institute has completed a successful animal study of nutritional supplementation with Rock Creek's specially formulated anatabine (patent pending), in an animal model of multiple sclerosis. The Roskamp Institute has previously reported on a successful study in a mouse model of Alzheimer's disease using nutritional supplementation with a specially formulated version of Anatabloc® (patent pending).

In this report, entitled "Preliminary results of the treatment of a mouse model of Multiple Sclerosis with anatabine," the researchers at Roskamp describe how they assessed the effects of nutritional supplementation of the animal's diet with an animal formulation of anatabine in EAE (experimental autoimmune encephalomyelitis). This condition is induced by vaccinating mice with myelin which induces an autoimmune reaction. As a consequence, there is a severe inflammatory process in the brain, which has the effect of destroying neurons and causing progressive paralysis. In this regard, the disease model looks very similar to that which occurs in human multiple sclerosis. Dietary supplementation with anatabine resulted in a dramatic reduction in the rate of paralysis of hind limbs [see figure 1].

In addition to the better motor performance of the mice, there was evidence of suppression of the normal inflammatory response that accompanies neuronal destruction in this model. In the affected animals that did not receive supplementation with an anatabine formulation, the spleen pro-inflammatory mole
'/>"/>

SOURCE Star Scientific, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Roskamp Institute Obtains IRB Approval for Multi-Site Human Clinical Trial with Rock Creek Pharmaceutical RCP-006 Compound
2. Star Scientific Comments on Roskamp Institutes Plans to Conduct Human Alzheimers Clinical Trials Using a Compound (RCP-006) Developed by Rock Creek Pharmaceuticals, Inc.
3. Roskamp Institute to Begin Human Alzheimers Clinical Trials With a Natural Compound in Tobacco
4. Roskamp Institute Announces Enrollment of First Students to Participate in its Innovative Research Doctorate Program
5. Roskamp Institute Identifies New Class of Drugs to Treat Alzheimers Disease
6. Sarasotas Roskamp Institute Highlights Positive Japanese Data that Validates its Ongoing Alzheimers Disease Research
7. Sarasotas Roskamp Institute Releases Study Defining a Mechanism for Development of Obesity and the Metabolic Syndrome, Forerunners of Type 2 Diabetes
8. University Hospitals Case Medical Centers Harrington Discovery Institute Launches Grant Program to Accelerate Drug Discovery and Development
9. Remedy Informatics Cardiovascular Registry Selected by World-Renowned Cleveland Clinic Heart and Vascular Institute
10. Galenea to Receive $6 Million From The Stanley Medical Research Institute to Progress Pro-Cognitive Drug Discovery and Development Program
11. Midwest Orthopaedics at Rush Minimally Invasive Spine Institute Opens Today
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/14/2014)... HILLSBORO, Ore. , Jan. 14, 2014 /PRNewswire-iReach/ -- ... and a targeting guide with accompanying instrumentation to place ... new adjunct to the soft tissue (e.g. ligament) repair ... soft tissue repair heals. (Photo: http://photos.prnewswire.com/prnh/20140114/MN45636 ...
(Date:1/14/2014)... a manufacturer of ergonomically designed laboratory equipment for research, ... Japan to sell and service the Hitachi brand ... utilize its network of sales professionals throughout the United ... assistance in application use, product benefits and features, options and accessories, ...
(Date:1/14/2014)... , Jan. 14, 2014   Oligomerix, Inc. , a privately ... for Alzheimer,s disease (AD) and related neurodegenerative disorders, announced ... Valhalla, NY as of January 15, ... at New York Medical College. Oligomerix, which ...
Breaking Medicine Technology:Acumed introduces the Scapho-Lunate Inter Carpal (SLIC) Screw System 2Acumed introduces the Scapho-Lunate Inter Carpal (SLIC) Screw System 3NuAire announces sales and service of Hitachi Koki centrifuges in North America 2Oligomerix Relocates Corporate Headquarters and Secures Additional Laboratory Space from New York Medical College 2
... Eisai Corporation of North America today announced that the ... review the company,s supplemental new drug application (sNDA) for ... injection) to treat patients with myelodysplastic syndromes (MDS). ... diseases that limit the production of functional blood cells. ...
... Amgen (Nasdaq: AMGN ) today announced that ... Zometa(R) (zoledronic acid) in the treatment of bone metastases ... primary and secondary endpoints and demonstrated superior efficacy compared ... the time to the first on-study Skeletal Related Events ...
Cached Medicine Technology:FDA Accepts sNDA for Alternative Dosing Regimen for Dacogen(R) (decitabine for injection) to Treat Patients with Myelodysplastic Syndromes (MDS) 2Denosumab Demonstrates Superiority Over Zometa(R) in Pivotal Phase 3 Head-to-Head Trial in Breast Cancer Patients With Bone Metastases 2Denosumab Demonstrates Superiority Over Zometa(R) in Pivotal Phase 3 Head-to-Head Trial in Breast Cancer Patients With Bone Metastases 3Denosumab Demonstrates Superiority Over Zometa(R) in Pivotal Phase 3 Head-to-Head Trial in Breast Cancer Patients With Bone Metastases 4Denosumab Demonstrates Superiority Over Zometa(R) in Pivotal Phase 3 Head-to-Head Trial in Breast Cancer Patients With Bone Metastases 5Denosumab Demonstrates Superiority Over Zometa(R) in Pivotal Phase 3 Head-to-Head Trial in Breast Cancer Patients With Bone Metastases 6Denosumab Demonstrates Superiority Over Zometa(R) in Pivotal Phase 3 Head-to-Head Trial in Breast Cancer Patients With Bone Metastases 7Denosumab Demonstrates Superiority Over Zometa(R) in Pivotal Phase 3 Head-to-Head Trial in Breast Cancer Patients With Bone Metastases 8
(Date:4/23/2014)... Oncotarget , explored tumour heterogeneity where different ... signatures within the same cancer. Such differences could ... strategies. , Firstly they confirmed the mutual exclusivity ... or BRAF mutation. Secondly, they found that lung ... that specific mutation present uniformly throughout the tumour, ...
(Date:4/23/2014)... bottom of Alzheimer,s disease has been a rapidly ... In the latest crook in the research road, ... interaction between proteins associated with the disease. The ... Chemical Neuroscience , could have important implications for ... Nieznanski and colleagues explain that for years, research ...
(Date:4/22/2014)... (Chicago) A recently FDA-approved device has been shown ... as much as 50 percent. When coupled with an ... Rush, the device facilitated the complete elimination of seizures ... in the decade-long clinical trials. , That,s good news ... in the U.S. living with epilepsy whose seizures can,t ...
(Date:4/22/2014)... April 22, 2014 Researchers at UT Southwestern Medical ... from depression . , A team of ... by which ghrelin (a hormone with natural anti-depressant properties) ... potentially powerful new treatment for depression in the form ... The study, published online in April,s issue of ...
(Date:4/22/2014)... Bethesda, MD, April 22, 2014: The Association for ... The Journal of Molecular Diagnostics on ... the baccalaureate and master,s levels of education. The ... (MLS) Curriculum Task Force of the AMP Training ... the critical need of educating future medical laboratory ...
Breaking Medicine News(10 mins):Health News:Non-uniform genetic mutations identified in lung cancers could lead to targeted treatment 2Health News:Newly approved brain stimulator offers hope for individuals with uncontrolled epilepsy 2Health News:Depressed? Researchers identify new anti-depressant mechanisms, therapeutic approaches 2Health News:Depressed? Researchers identify new anti-depressant mechanisms, therapeutic approaches 3Health News:AMP publishes curriculum recommendations for medical laboratory scientists 2
... blood vessel walls can vary among individuals depending on factors ... research at UC Davis. The new research reinforces the ... linings that can lead to heart disease and strokes. ... cholesterol," known to increase risk of inflammation of the endothelium, ...
... Salamon HealthDay Reporter , THURSDAY, Feb. 17 (HealthDay ... weeks early has no discernible impact on babies, a new ... than their full-term peers and those delays may affect their ... term and 1,200 late preterm infants -- those born between ...
... 2011) Two studies published in the current issue ... islet cell transplantation for treating diabetes. Researchers in Milan, ... in diabetic therapy and islet cell regeneration and Canadian ... in vitro. Both studies are in the ...
... Feb. 17 (HealthDay News) -- The area of the brain ... that suggests the brain is a "task machine" instead of ... brain scans, the researchers measured neural activity in eight blind ... blind since birth, showed activity in the exact same part ...
... cell phone use does not appear to increase the ... a study by University of Manchester scientists suggests. ... Office of National Statistics to look at trends in ... 1998 and 2007. The study, published in the ...
... urban public housing spend more time playing outdoors than ... Columbia University and Princeton University. Contrary to ... living in poorer circumstances would be playing outside less, ... played outside 13 percent more per day, on average, ...
Cached Medicine News:Health News:Study reinforces link between obesity, high-fat meals and heart disease 2Health News:Delivery Even a Bit Early May Mean Developmental Delays 2Health News:Delivery Even a Bit Early May Mean Developmental Delays 3Health News:Researchers work at the frontiers of islet cell transplantation 2Health News:Researchers work at the frontiers of islet cell transplantation 3Health News:Cell-phone use not related to increased brain cancer risk 2Health News:Children in public housing play outdoors more 2
Three-spring evacuator kits with silicone drains, 10 in. hole pattern, trocar and Y-connector tubing...
Reliavac® 400cc kits with silicone round drain with 10 in. hole pattern, trocar, and Y-connector tubing...
Reliavac 100cc evacuators offer a more constant suction profile than silicone evacuators. 100cc capacity is easy for patient to carry. Bottom emptying port reduces chance of contamination....
Used in the peritoneal cavity to remove large volumes of thick exudate....
Medicine Products: